Drug Trial Radar · NCT07704840
A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Alberto EsquenaziAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Conditions
- Post-Stroke Spasticity
Interventions
Administration of BMS-986368Drug
Administration of BMS-986368. Specified dose on specified days
PlaceboDrug
Interventions: Drug: Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tardieu ScaleTime frame: At Week 8
- Upper Limb Fugl-Meyer Assessment (FMA-UE) ScaleTime frame: At Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jeffersi=on Moss Magee Rehabilitation
Elkins Park, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.